Literature DB >> 6089420

Lymphocytic choriomeningitis virus. VIII. Reciprocal formation of pseudotypes with vesicular stomatitis virus.

M Bruns, F Lehmann-Grube.   

Abstract

Large numbers of VSV (LCMV) pseudotypes with the genomes of vesicular stomatitis virus (VSV) and the coat proteins of lymphocytic choriomeningitis virus (LCMV) were produced by infecting L cells first with LCMV and subsequently with VSV, the latter in the presence of tunicamycin. Separation by gradient centrifugation from the concomitantly produced LCMV genotypes, followed by polyacrylamide gel electrophoresis (PAGE), failed to reveal measurable quantities of the one glycoprotein ("G") of VSV. By serologic analysis it could be shown that anti-VSV antibody still attached, although with low efficiency. VSV (LCMV) retained its infectivity during purification. Reversal of the sequence of infection under otherwise identical conditions led to the formation of LCMV (VSV) pseudotypes. When separated from VSV genotypes, PAGE did not disclose glycoproteins of LCMV, and serologic analysis failed to detect attachment of anti-LCM virus antibody. LCMV (VSV) lost its infectivity during purification.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6089420     DOI: 10.1016/0042-6822(84)90007-2

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  3 in total

1.  Studies on the mechanism of lymphocytic choriomeningitis virus homologous interference.

Authors:  M Bruns; W Zeller; F Lehmann-Grube
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

2.  Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein.

Authors:  Daniel D Pinschewer; Mar Perez; Ana B Sanchez; Juan Carlos de la Torre
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

3.  Immunotherapy of WAP-TNP mice with early stage mammary gland tumors.

Authors:  Michael Bruns; Wolfgang Deppert
Journal:  Oncotarget       Date:  2017-06-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.